➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
Merck
AstraZeneca
Express Scripts

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Polidocanol - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for polidocanol and what is the scope of freedom to operate?

Polidocanol is the generic ingredient in two branded drugs marketed by Chemisch Fbrk Krsslr and Provensis, and is included in two NDAs. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Polidocanol has one hundred and eighty-nine patent family members in thirty-nine countries.

Two suppliers are listed for this compound.

Summary for polidocanol
International Patents:189
US Patents:14
Tradenames:2
Applicants:2
NDAs:2
Suppliers / Packagers: 2
Bulk Api Vendors: 42
Clinical Trials: 22
Patent Applications: 3,040
Formulation / Manufacturing:see details
DailyMed Link:polidocanol at DailyMed
Recent Clinical Trials for polidocanol

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of the Republic, UruguayPhase 4
Centro Cardiovascular UniversitarioPhase 4
Hospital de Clínicas Dr. Manuel QuintelaPhase 4

See all polidocanol clinical trials

Pharmacology for polidocanol
Drug ClassSclerosing Agent
Mechanism of ActionSclerosing Activity
Physiological EffectVascular Sclerosing Activity

US Patents and Regulatory Information for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chemisch Fbrk Krsslr ASCLERA polidocanol SOLUTION;INTRAVENOUS 021201-001 Mar 30, 2010 RX Yes No   Start Trial   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for polidocanol

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
McKinsey
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.